JAK-inhibitors and risk on serious viral infection, venous thromboembolism and cardiac events in patients with rheumatoid arthritis: A protocol for a prevalent new-user cohort study using the Danish nationwide DANBIO register

Janus Kinase inhibitors (JAKis) are targeted synthetic disease-modifying antirheumatic drugs and represent an important alternative to treat patients with moderate to high rheumatoid arthritis (RA) disease activity. Safety concerns associated with increased risk for venous thromboembolism (VTE), ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Faquetti, Maria Luisa, Vallejo-Yagüe, Enriqueta, Cordtz, René, Dreyer, Lene, Burden, Andrea M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374052/
https://www.ncbi.nlm.nih.gov/pubmed/37498856
http://dx.doi.org/10.1371/journal.pone.0288757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374052/
https://www.ncbi.nlm.nih.gov/pubmed/37498856
http://dx.doi.org/10.1371/journal.pone.0288757

Ejemplares similares